Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
-
CAR t therapy takes on rare muscle-stiffening disease
Disease control OngoingThis study tests a new treatment called KYV-101 for people with stiff person syndrome, a rare disease that causes severe muscle stiffness and spasms. The treatment uses a patient's own immune cells, modified to target and calm the immune system. The study will enroll 25 adults to…
Phase: PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
Immune cell therapy shows promise for tough lupus kidney cases
Disease control OngoingThis early-stage study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the disease. The study aims to chec…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:07 UTC
-
Experimental CAR t therapy takes aim at lupus kidney disease
Disease control OngoingThis early-phase study tests a new treatment called KYV-101 for people with lupus nephritis (kidney inflammation from lupus) that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells. The main goal…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
CAR-T therapy takes on scleroderma: a new hope for patients
Disease control OngoingThis early-stage study tests a new treatment called KYV-101 for people with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. The therapy uses a patient's own modified immune cells to target and destroy faulty B-cells. The main goals are to check…
Phase: PHASE1, PHASE2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated May 26, 2026 02:48 UTC